After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
We have now added a new section called the "Assay History List" to the "At A Gla...